# Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma

> **NCT01468311** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 6 (actual)

## Conditions studied

- Hodgkin Disease
- Hodgkin Lymphoma

## Interventions

- **PROCEDURE:** Auto stem cell transplant
- **DRUG:** BEAM
- **RADIATION:** 111In-daclizumab
- **RADIATION:** 90Y-daclizumab

## Key facts

- **NCT ID:** NCT01468311
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10-11
- **Primary completion:** 2014-11-16
- **Final completion:** 2020-10-22
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Poor enrollment and ability to radioconjugate Daclizumab. Neither Center for Cancer Research (CCR) or Nuclear Medicine/Radiology wanted to do the facilities upgrade and hire personnel needed to radioconjugate the drug at the Clinical Center.
- **Last updated:** 2021-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01468311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01468311, "Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01468311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*